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Repetitive sequence–based polymerase chain reac-
tion fingerprinting was used to characterize 23 vancomycin-
nonsusceptible enterococcal isolates from 2003 to 2004.
Five genetically related clusters spanned geographically
distinct referring centers. DNA fingerprinting showed infant-
to-infant transmission from referring institutions. Thus,
community healthcare facilities are a source of vanco-
mycin-nonsusceptible enterococci and should be targeted
for increased infection control efforts.
V
ancomycin-resistant enterococci (VRE) are a cause of
nosocomial infections in US hospitals. The National
Nosocomial Infections Surveillance system of the Centers
for Disease Control and Prevention reported vancomycin
resistance in 28.5% of nosocomial enterococcal intensive
care unit infections in 2003 (1). In a recent study, 14% of
VRE-colonized patients progressed to infection within 15
days of a positive surveillance culture (2). Moreover, VRE
can transfer the vanA gene for vancomycin resistance to
more virulent pathogens such as Staphylococcus aureus
both in vitro and in vivo (3).
Risk factors for VRE colonization in children include
young age, use of invasive devices, antimicrobial drug
administration, immunosuppression, low birth weight, and
underlying malignancy (4). Interfacility transfer of patients
colonized with VRE is common, and previous hospitaliza-
tion is a risk factor for harboring VRE at the time of hos-
pital admission (5,6). Active surveillance culture (ASC)
programs for VRE and aggressive implementation of
infection control measures reduce VRE transmission
among adult and pediatric patients (7,8).
We identified our first VRE-infected patient (bac-
teremia and urinary tract infection) in our neonatal inten-
sive care unit (NICU) in 2000. This occasion prompted the
initiation of our own ASC program. During the next 3
years (2000–2002), 65 patients with VRE colonization or
infection were identified among the 1,820 patients admit-
ted to our NICU. Of the VRE-colonized or -infected
patients, some experienced serious infections, such as
meningitis and bacteremia, while others were completely
asymptomatic (9). By 2002, a multifaceted intervention
greatly reduced the intrahospital spread of VRE. We con-
tinued our ASC program in the NICU during 2003–2004.
An additional 25 patients were found to be colonized with
vancomycin-nonsusceptible enterococci (VNSE); this
group includes VRE and enterococci with intermediate
susceptibility to vancomycin. All infants colonized with
VRE had been admitted directly from regional hospitals in
the Washington, DC, metropolitan area. This is the first
study in which an ASC program and repetitive
sequence–based polymerase chain reaction (Rep-PCR)
fingerprinting were used to characterize the genetic relat-
edness and document intrahospital spread of VNSE.
The Study
The NICU at Children’s National Medical Center
(CNMC) is a level III/IV 40-bed unit that provides care for
critically ill patients in the first 6 months of life. CNMC has
no obstetrics service; therefore, all NICU admissions are
referrals from other hospitals. Our ASC program for VNSE
included rectal swab cultures performed upon admission to
the NICU. Repeat cultures were collected weekly from
patients with negative admission cultures unless they
became colonized or were discharged. Dacron-tipped
swabs were moistened with sterile trypticase soy broth
before rectal sampling. All neonates with VRE were placed
on contact isolation during their NICU hospitalization. 
Rectal swab specimens were added to Campylobacter
blood agar plates containing 10 µg/mL vancomycin
(Becton Dickinson Diagnostic Systems, Sparks, MD,
USA). VRE were identified by using standard laboratory
procedures. Species identification and vancomycin sus-
ceptibility were determined by using MicroScan Gram-
Positive Breakpoint Combo Panels (Dade Behring,
Deerfield, IL, USA) with a 24-hour incubation.
Vancomycin susceptibility results were categorized
according to the standards published by the Clinical and
Laboratory Standards Institute (10). Susceptible isolates
had vancomycin MICs <4 µg/mL, intermediate isolates
had MICs 8–16 µg/mL, and resistant isolates had MICs
> 32  µg/mL.  Enterococcus faecium and  E. gallinarum
were differentiated by using standard laboratory tests for
motility and detection of acid production from xylose
(11).
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Health, Washington, DC, USAThe genetic relatedness of 23 VNSE was determined
with Rep-PCR DNA fingerprinting by procedures recently
described (12). Briefly, DNA was extracted from 2 µLo f
an overnight VNSE culture by using the Ultraclean
Microbial DNA Isolation Kit (Mo Bio Laboratories,
Carlsbad, CA, USA). The extracted DNA was amplified
by Rep-PCR by using the DiversiLab Enterococcus Kit
(Bacterial Barcodes, Spectral Genomics, Houston, TX,
USA). 
The Rep-PCR products were analyzed by using the
DiversiLab System and Software (Bacterial Barcodes,
Spectral Genomics). The resulting DNA fingerprint pat-
terns were viewed as virtual electropherograms. Analysis
was performed with DiversiLab software version 2.1.6.6
by using Pearson correlation coefficients to determine
genetic similarities and the unweighted pair group method
with arithmetic mean to create dendrograms. Samples
were classified into 3 groups: indistinguishable (similarity
>97%), similar (similarity 95%–97% with fingerprint pat-
terns displaying 1–2 band differences), and different (sim-
ilarity <95% with >2 band differences) (12).
Of 1,333 NICU patients admitted during 2003–2004, a
total of 25 were colonized with VNSE, yielding a coloniza-
tion rate of 2%. The median age of these patients was 45
days (range 14–200 days). Twenty-three isolates were
available for DNA analysis. Fifteen (65%) of the 23 iso-
lates were E. gallinarum, and all had intermediate suscep-
tibility to vancomycin. The remaining 8 isolates (35%)
were E. faecium and all were vancomycin resistant. Rep-
PCR analysis identified 5 distinct fingerprinting patterns
with >95% similarities (Figure). The genetically related
clusters are grouped as C1 (isolates 1–5, vancomycin-
resistant E. faecium), C2 (isolates 9–12, vancomycin-inter-
mediate E. gallinarum), C3 (isolates 13–14, vancomycin-
intermediate E. gallinarum), C4 (isolates 15–20, van-
comycin-intermediate E. gallinarum), and C5 (isolates
22–23, vancomycin-intermediate E. gallinarum).
Enterococcus isolates 6, 7, and 8 (vancomycin-resistant E.
faecium) and 21 (vancomycin-intermediate E. gallinarum)
were genetically unique and unrelated to all other isolates
tested. The similarity coefficients among members of each
of the dominant clusters were >95% and the band differ-
ences were minor (i.e., only 1 or 2 band differences were
found when gel images were compared with those of other
cluster members). In cluster C1, 2 of the 4 isolates of E.
faecium (isolates 1 and 2) had similarity coefficients >99%
and were recovered from infants transferred from the same
medical center. Both infants were admitted to our NICU
within 2 weeks of each other. In cluster C4, 2 of 6 isolates
of E. gallinarum (isolates 16 and 18) had similarity coeffi-
cients >98% and were recovered from patients transferred
from the same medical center.
Conclusions 
Because VRE can colonize the gastrointestinal tract for
a prolonged period without progressing to clinically appar-
ent disease, early recognition of colonization is essential
for preventing patient-to-patient transmission. Of the 25
infants colonized with VNSE identified by our ASC pro-
gram in 2003–2004, 23 isolates were available for DNA
fingerprinting and further characterization. Thirty-five per-
cent of the patients harbored vancomycin-resistant E. fae-
cium, and 65% had vancomycin-intermediate E.
gallinarum. Although E. gallinarum has low-level intrinsic
vancomycin resistance and, thus, provokes fewer infection
control concerns than high-level vancomycin-resistant E.
faecium, invasive infections with this pathogen have been
documented (13). The initiation of our ASC program, cou-
pled with accurate and timely identification of VNSE, was
associated with a sharp decrease in transmission of these
bacteria to other NICU patients. 
Molecular typing of VRE isolates with PCR and con-
tour-clamped homogeneous electric field electrophoresis
to conduct restriction fragment length polymorphism
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Figure. Dendrogram of 23 nonsusceptible enterococci isolates.
Genetically related clusters are labeled C1–C5. Isolates repre-
sented by lanes 6, 7, 8, and 21 are genetically distinct. analysis of specific enterococcal genes has been described
(14). These techniques enable targeted analysis of specific
portions of the VRE genome and strain characterization.
However, the overall genetic similarity of strains is
unknown because only a small portion of the genome is
assessed by these methods. Rep-PCR DNA fingerprinting
is faster and easier to use than the other methods and
results in a high level of genetic discrimination, making it
a useful molecular epidemiologic tool.
Rep-PCR DNA fingerprinting identified 5 dominant
clusters of VNSE in our NICU study patient population.
Two instances of strong genetic relatedness were observed
in isolates from neonates who were transferred from the
same referral center within a limited period of time. The
close relatedness of other VNSE was independent of the
patient’s hospital of origin. Infants from the same referral
center usually did not have strains that were genetically
related. One study described 7 VRE strains from 3 differ-
ent locations within the same institution (14). Another
study characterized VRE isolates from 6 different hospitals
and found 23 isolates of 3 related types at 1 institution,
while all isolates from another hospital were genetically
distinct (15).
Referring centers that had transferred patients with
VNSE to our NICU were informed of our results. As a
result of our investigation, which showed no patient-to-
patient transmission in our NICU during the study period,
we established the following procedures: 1) we obtained
ASC for VRE only from infants >14 days of age on admis-
sion to the NICU and placed them on contact isolation
pending results, and 2) we no longer perform weekly sur-
veillance cultures on previously culture-negative patients.
This approach is cost-effective and sustainable.
Our ASC program identified a significant number of
neonates admitted to our NICU who had been previously
unrecognized as colonized with VNSE. Molecular finger-
printing of their isolates identified the existence of 5 clus-
ters and several unique strains of VNSE circulating among
newborns born in Washington, DC, metropolitan area hos-
pitals. Our data also suggested that referring centers had
experienced infant-to-infant spread based on similar Rep-
PCR DNA fingerprint patterns. Our ASC program in tan-
dem with the implementation of appropriate infection
control measures led to a decrease in transmission of VRE
to other NICU patients.
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